YJ. Biotechnology Co.,Ltd

Name

YJ. Biotechnology Co.,Ltd

Legal name

YJ. Biotechnology Co.,Ltd

Website

https://yj-bio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Cell Manufacturing Equipment

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Cell Therapy CDMO (HLAGABAD)

akta.pro secondary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

Keywords

• Cell manufacturing equipment
• Pharmaceutical isolator systems
• GMP cell production
• CDMO cell therapy services
• Exosome manufacturing technology

Headquarters

HQ city

New City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Equipment Sales (YJ-Isolator and related equipment): Sale and installation of the proprietary YJ-Isolator system and related pharmaceutical-grade manufacturing equipment (filling lines, lyophilizers, capping systems) to medical institutions and biotechnology companies.
2. CDMO Services (Contract Development and Manufacturing Organization): Exosome contract manufacturing, sterile filling, and freeze-drying services; stem cell and immune cell contract manufacturing; OEM services for exosome-based beauty products; technology development services.
3. Turn-Key Factory Planning and Setup Services: Complete design, construction, and operational maintenance services for micro-intelligent cell preparation factories, including URS definition, layout design, IQ/OQ/PQ validation, regulatory certification, and technical services.
4. Cell Manufacturing Technology Licensing: Licensing of proprietary cell manufacturing processes, SOPs, and technology to partners for clinical and commercial cell therapy production.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

YJ. Biotechnology develops and manufactures the YJ-Isolator, Taiwan's first domestically produced pharmaceutical-grade aseptic isolation device purpose-built for cell mass production, and provides an integrated cell manufacturing platform combining high-efficiency cell expansion, AIoT process monitoring, and PIC/S GMP-compliant isolator technology. The company sells equipment, turnkey factory design/build services, CDMO cell and exosome contract manufacturing, and licenses its cell manufacturing technology to medical institutions and biotech companies.

Product overview

YJ. Biotechnology Co.,Ltd offers an integrated cell manufacturing platform combining the YJ-Isolator as the core pharmaceutical-grade isolation system with supporting modules (AIoT monitoring, aseptic filling, lyophilization, and vial capping). The platform enables decentralized point-of-care cell manufacturing for immune cells, stem cells, and exosomes under PIC/S GMP conditions. The company provides turnkey factory design/build/operation services, CDMO manufacturing services, and quality testing under ISO/IEC 17025 certification.

Differentiator

Problem solved

Functional benefit

Products and services

• YJ-Isolator (Cell Pharmaceutical Aseptic Isolation Device) Taiwan's first domestically manufactured pharmaceutical-grade isolator specifically designed for large-scale cell manufacturing. Features modular, miniature, and intelligent design with RTP fast-connect incubator, H2O2 sterilizer, microscope, and centrifuge integrated into a Class A ISO 5 environment within ISO 8 background, complying with PIC/S GMP standards. Sold to medical institutions and biotechnology companies.
• AIoT Cell Process System (AIoT Cell Manufacturing Process) AIoT-driven cell manufacturing monitoring system combining artificial intelligence and IoT technology for real-time environmental monitoring and data recording. Includes AI auxiliary decision support, digital production records, and remote IoT factory monitoring compliant with FDA 21 CFR Part 11. Sold as a standalone platform to biotech and pharma manufacturers.
• YJ Aseptic Bio-Filling Line (YJ-52403) Aseptic filling equipment integrated with H2O2 sterilization and RTP (Rapid Transfer Port) systems for automated filling within a Class A environment. Sold as a standalone equipment unit to biotech manufacturers and CDMO clients.
• YJ Shelf Lyophilizer (YJ-52404) Freeze-drying equipment with dual-chamber design and precise temperature control for efficient lyophilization, designed for integration with the YJ-Isolator platform for closed-system aseptic freeze-drying of exosomes and biologics.
• YJ Vial Capping Line (YJ-52405) Automated vial capping system that completes vial sealing within the closed isolator environment without exposure to open areas, enabling the complete aseptic production line for injectable and lyophilized products.
• Mini Intelligent Cell Therapy Product Factory (Turnkey Factory Solution) Turnkey solution for designing, constructing, and operating decentralized point-of-care cell manufacturing facilities. Combines modular design with exclusive high-efficiency processes for cell mass production in limited spaces with economic benefits. Includes URS definition, layout design, IQ/OQ/PQ validation, regulatory certification, and technical services for hospitals and biotech companies.
• Exosome Products Human umbilical cord-derived exosome products available in 500 billion and 3000 billion vesicle specifications. Produced using aseptic lyophilization technology allowing room temperature storage for one year with 90% bioactivity retention after reconstitution. Supplied to biotech companies and medical aesthetics brands.
• Immune Cell Therapy Products Cell therapy products including CIK (Cytokine-Induced Killer Cells), NK (Natural Killer Cells), DC-CIK, and gamma-delta T cells for cancer treatment applications, manufactured under GMP-compliant conditions and supplied to medical institutions for clinical use.
• Stem Cell Products Stem cell products including umbilical cord mesenchymal stem cells (UC-MSCs) and adipose-derived stem cells (ADSCs) for regenerative medicine applications including neurological, cardiovascular, and orthopedic treatments. Supplied to hospitals and research institutions.
• CDMO Contract Development and Manufacturing Services Contract development and manufacturing services including exosome OEM cosmetics, exosome manufacturing with aseptic filling and lyophilization, technical development, and cell manufacturing services for biotech and pharmaceutical clients.

Quantifiable outcome

• 80% reduction in electricity costs compared to traditional cleanroom manufacturing
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: Global leader in cell and gene therapy CDMO services with multiple GMP manufacturing sites. Comparable as a large incumbent offering commercial-scale cell therapy manufacturing services and equipment, though operating a centralized mega-factory model rather than YJ's decentralized point-of-care thesis.
• Cytiva (Danaher): Major bioprocessing equipment and services provider under Danaher, supplying cell therapy manufacturing infrastructure globally. Comparable in providing cell therapy manufacturing equipment and services, though as part of a much broader bioprocessing portfolio.
• Catalent: Major global CDMO with cell therapy development and manufacturing capabilities across biologics and gene therapy. Comparable in providing contract cell manufacturing services, but at much larger scale and broader modality coverage than YJ's specialized cell therapy focus.
• AGC Biologics: Global CDMO with cell therapy, gene therapy, and biologics manufacturing capabilities. Comparable in providing cell therapy contract manufacturing services, though offering a broader portfolio of services at commercial scale versus YJ's specialized point-of-care focus.
• WuXi Biologics: Asia's largest biologics CDMO with growing cell therapy capabilities and a similar Asia-Pacific geographic footprint. Comparable as a CDMO serving cell therapy developers in the region, though operating at much larger scale and broader modality coverage.

Emerging players

• Ori Biotech: Cell and gene therapy manufacturing platform company focused on automated, closed-system cell processing. Comparable as an emerging player pursuing decentralized and scalable cell therapy manufacturing, though focused on process automation rather than pharmaceutical-grade isolators.
• CellGenix (Sartorius): Cell and gene therapy raw materials and manufacturing services provider now part of Sartorius. Comparable as a supplier to cell therapy manufacturers with GMP-grade products, though focused on media and reagents rather than manufacturing equipment platforms.

Direct peers

• Cellares: US-based cell therapy manufacturing automation company pursuing a similar decentralized point-of-care manufacturing thesis. Directly comparable as both companies target automated, closed-system cell manufacturing closer to patients, though Cellares focuses on automation robotics versus YJ's isolator-based approach.
• Miltenyi Biotec: Cell processing technology and instrument provider serving cell therapy developers and research institutions globally. Comparable in providing equipment and consumables for cell manufacturing, including closed-system processing devices, though focused on magnetic cell separation rather than pharmaceutical isolators.
• ThermoGenesis (a Boai NKY company): Cell processing and cryopreservation equipment provider for cell therapy applications. Comparable as a provider of automated cell manufacturing and processing equipment used by hospitals and cell therapy developers, though focused on cryopreservation rather than aseptic isolator-based production.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@YJ-bio
• Facebookfacebook.com/YJ.biotech?mibextid=LQQJ4d
• LinkedInlinkedin.com/company/yj-biotech
• Instagraminstagram.com/yj.biotech

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about YJ. Biotechnology Co.,Ltd